BIOMEA FUSION
Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to create more effective therapies for cancer patients. Biomea Fusion has a development portfolio that targets specific gene alterations which occur in the DNA of patients that translate into key drivers of tumor growth. It is Biomea’s goal to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful treatments for patients in need. The lead program targets the protein-to-protein interaction between menin and the MLL complex for the treatment of various tumors.
BIOMEA FUSION
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Redwood City, California, United States
Country:
United States
Website Url:
http://www.biomeafusion.com
Total Employee:
11+
Status:
Active
Contact:
(650) 980-9099
Total Funding:
56 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Epirium Bio
Epirium Bio is a biopharmaceutical company developing a small molecule platform targeting improvements in muscle strength.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Nuvalent
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Ramses Erdtmann Co-Founder & President @ Biomea Fusion
Co-Founder & President
Thomas Butler Co-Founder & CEO @ Biomea Fusion
Co-Founder & CEO
Steve Morris Chief Medical Officer @ Biomea Fusion
Chief Medical Officer
2022-02-01
Founder
Stock Details
Investors List
Point Sur Investors
Point Sur Investors investment in Series A - Biomea Fusion
Aisling Capital
Aisling Capital investment in Series A - Biomea Fusion
Logos Capital
Logos Capital investment in Series A - Biomea Fusion
Janus Henderson Investors
Janus Henderson Investors investment in Series A - Biomea Fusion
Rock Springs Capital
Rock Springs Capital investment in Series A - Biomea Fusion
Cormorant Asset Management
Cormorant Asset Management investment in Series A - Biomea Fusion
Boxer Capital
Boxer Capital investment in Series A - Biomea Fusion
RTW Investments LLC
RTW Investments LLC investment in Series A - Biomea Fusion
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | Biomea Fusion Announces Appointment of Steve Morris, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.biomeafusion.com Semrush global rank: 1.17 M Semrush visits lastest month: 26.74 K
- Host name: 119.0.153.160.host.secureserver.net
- IP address: 160.153.0.119
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Biomea Fusion"
Investors & Media | Biomea Fusion
Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook. Corporate Presentation - May 2025. Stock Quote. Change Volume 52 Week High 52 Week Low May 25, …See details»
QUICK FACTS – Biomea Corporate Overview and Programs
Www.biomeafusion.com . QUICK FACTS – Biomea Corporate Overview and Programs . Overview. We are a clinical-stage biopharmaceutical company (NASDAQ: BMEA) focused on …See details»
Biomea Fusion, Inc. (BMEA) Company Profile & Facts - Yahoo …
See the company profile for Biomea Fusion, Inc. (BMEA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Biomea Fusion - Crunchbase Company Profile & Funding
Contact Email info@biomeafusion.com Phone Number (650) 980-9099 Biomea Fusion is a privately held precision medicine company with a mission to revolutionize drug development to …See details»
Biomea Fusion (BMEA) Company Profile & Description - Stock …
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically …See details»
Biomea Fusion Reports First Quarter 2025 Financial Results and ...
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Forward-Looking Statements. Statements we make in this press release may include statements which are not …See details»
Biomea Fusion, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Biomea Fusion, Inc. of Redwood City, CA. Get the latest business insights from Dun & Bradstreet.See details»
Biomea Fusion: Contact Details, Revenue, Funding, Employees and …
Biomea Fusion is a biopharmaceutical company focused on discovering and developing oral covalent small molecules to treat metabolic diseases and genetically defined cancers.See details»
Biomea Fusion 2025 Company Profile: Stock Performance
Biomea Fusion General Information Description. Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent …See details»
Press Releases - Biomea Fusion
Mar 24, 2025 REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, …See details»
Biomea Fusion, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
May 7, 2025 Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Contact:Ramses ErdtmannCOO & President of Biomea Fusion re@biomeafusion.com . Phase …See details»
Biomea Fusion Announces Leadership Transition - BioSpace
Mar 26, 2025 Board member Mick Hitchcock named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, …See details»
Biomea Fusion to Present at the 39th Annual J.P. Morgan …
Jan 8, 2021 A live audio webcast of the presentation can be accessed at www.biomeafusion.com and will be available for 30 days following the presentation. About …See details»
Biomea Fusion Company Profile - Office Locations, Competitors
Oct 29, 2024 Biomea Fusion has 2 employees at their 1 location. See insights on Biomea Fusion including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Biomea Fusion Announces Approval of “icovamenib” as …
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and …See details»
th Annual J.P. Morgan - biomeafusion.com
Jan 11, 2021 BMF-219 rapidly shuts down MLL-rearranged AML 12 0 1,000,000 2,000,000 3,000,000 4,000,000 5,000,000 T4 T7 T11 T14 Cell Viability @ 0.190uM MI-503 BMF-219 DMSOSee details»
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
Jan 13, 2025 Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which …See details»
Ask Me Anything - Biomea Fusion
Nov 27, 2024 Ask the Biomea Fusion team anything about covalent small molecules being to treat patients with genetically defined cancers.See details»
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial ...
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not …See details»
Biomea Fusion Reports First Quarter 2025 Financial Results and ...
May 5, 2025 --Biomea Fusion, Inc., a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2025, and provided a …See details»